Answers are grounded in this paper and cite their sources.
FDA's public release reveals rejection of MDMA therapy for PTSD, suggesting issues with study design and treatment durability.
In a historic move toward transparency, the U.S. Food and Drug Administration (FDA) on Sept. 4 publicly released its Complete Response Letter (CRL) rejecting the approval of midomafetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD). The letter, sent to Lykos Therapeutics in August 2024, outlines concerns about treatment durability, study design and prior MDMA use among participants — issues that critics say were not flagged during earlier protocol discussions.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: